Selonsertib, a selective inhibitor of ASK1, has been reported as an effective treatment for non-alcoholic steatohepatitis (NASH) and multidrug resistance (MDR) in various types of cancer in human patients by reducing hepatic steatosis, inflammation and fibrosis or reversing ATP-binding cassette transporter-mediated MDR [8, 9]. This evidence concerns the gene MAP3K5 and Hepatic steatosis.